Suzanne McBride

Dec 28, 2024 | chicago.suntimes.com | Suzanne McBride

When President Joe Biden last week spared the lives of 37 prisoners on federal death row, I thought of the men and women who guard the condemned, who administer the lethal dose of drugs, who remove the body from the execution chamber, who complete tasks many of us could not do. As a reporter who covered the death penalty in Indiana in the 1990s, I interviewed many people who worked in the state prison system and on death row.

Sep 20, 2024 | cancertodaymag.org | Suzanne McBride

Mike Herman makes a point to share the experiences he’s had participating in clinical trials with other people with cancer. Since being diagnosed with multiple myeloma in 2013, he has described how he benefited from two experimental drugs—one of which has recently been approved by the Food and Drug Administration.

Jun 21, 2024 | cancertodaymag.org | Suzanne McBride

IT’S THE NEWS NO ONE WANTS TO HEAR: You could have cancer. But in October 2015, that was the wake-up call that spurred Brian Jones to finally get serious about his health after years of neglecting his body. Jones, a pharmacy fulfillment manager, had passed out at work for the third time that fall. In the aftermath, his wife, Angie, insisted he see their primary care physician (PCP). At the appointment, his doctor told him, “You’re killing yourself,” as Angie Jones nodded in agreement.

Apr 5, 2024 | cancertodaymag.org | Laura Gesualdi-Gilmore |Sandra Gordon |Taneia Surles |Suzanne McBride

Every week, the editors of Cancer Today magazine bring you the top news for cancer patients from around the internet. Stay up to date with the latest in cancer research and care by subscribing to our e-newsletter. More people with cancer are taking part in clinical trials, according to a study published online April 2 in the Journal of Clinical Oncology.

Apr 2, 2024 | brnw.ch | Laura Gesualdi-Gilmore |Sandra Gordon |Taneia Surles |Suzanne McBride

A NEW GUIDELINE released by the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) recommends that all women diagnosed with breast cancer who are 65 years old or younger should be offered germline genetic testing for BRCA1 and BRCA2 mutations.